13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001055951
Total reported value
$5.4B
$5.4B
113 檔
28.5%
During the Q3 2024 filing period, Orbimed Advisors LLC (CIK: 0001055951) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $5.4B across 113 reported positions.
Orbimed Advisors LLC executed strategic sector rebalancing during Q3 2024, establishing 21 new positions while fully exiting 18 holdings and trimming 31 positions.
In terms of portfolio concentration, the top 5 core holdings (including EWTX, SVA, LLY) accounted for 28.5% of total reported equity market value during Q3 2024.
Top New Position Initiated
MBX
市值: $99.0M
Top Position Liquidated / Trimmed
VRNA
前期市值: $41.4M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 7.28% | +1.73% | — | |
| 2 | SVA | Sinovac Biotech Ltd. | Stock-Other | 6.18% | +3.06% | — | |
| 3 | LLY | Eli Lilly & Co | Stock-Healthcare | 5.43% | +1.30% | — | |
| 4 | BSX | Boston Scientific CORP | Stock-Healthcare | 4.98% | -1.88% | — | |
| 5 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 3.87% | -0.80% | -12.03% | |
| 6 | ELVN | Enliven Therapeutics Inc | Stock-Other | 3.69% | +0.02% | — | |
| 7 | BIIB | Biogen Inc | Stock-Healthcare | 2.86% | +0.02% | -9.76% | |
| 8 | MRK | Merck & Co. Inc. | Stock-Healthcare | 2.72% | -0.05% | — | |
| 9 | THC | Tenet Healthcare CORP | Stock-Healthcare | 2.36% | — | -33.35% | |
| 10 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 2.28% | — | +44.32% | |
| 11 | SYK | Stryker CORP | Stock-Healthcare | 2.26% | -0.30% | +28.03% | |
| 12 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 2.18% | -0.12% | -10.31% | |
| 13 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.01% | -0.44% | -2.20% | |
| 14 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.90% | +1.33% | NEW | |
| 15 | QTTB | Q32 Bio Inc | Stock-Other | 1.83% | +0.68% | — | |
| 16 | MBX | Mbx Biosciences Inc | Stock-Other | 1.80% | +1.30% | — | |
| 17 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.69% | — | -2.02% | |
| 18 | IRON | Disc Medicine Inc | Stock-Other | 1.59% | -0.91% | — | |
| 19 | NTRA | Natera Inc | Stock-Healthcare | 1.59% | +0.26% | — | |
| 20 | AMGN | Amgen Inc | Stock-Healthcare | 1.48% | -0.29% | EXIT | |
| 21 | ✓ | Third Harmonic Bio Inc | Stock-Other | 1.42% | — | — | |
| 22 | ITGR | Integer Holdings CORP | Stock-Healthcare | 1.36% | — | +64.65% | |
| 23 | AVBP | Arrivent Biopharma Inc | Stock-Other | 1.29% | +0.53% | — | |
| 24 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 1.28% | — | — | |
| 25 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.25% | -0.71% | — | |
| 26 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.15% | — | -0.74% | |
| 27 | KROS | Keros Therapeutics Inc | Stock-Other | 1.07% | -0.02% | -19.70% | |
| 28 | JANX | Janux Therapeutics Inc | Stock-Other | 1.04% | -0.13% | -57.76% | |
| 29 | ELV | Elevance Health Inc | Stock-Healthcare | 1.00% | +0.21% | -36.82% | |
| 30 | EVH | Evolent Health Inc - A | Stock-Other | 0.99% | — | -26.18% | |
| 31 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.97% | -0.04% | -18.02% | |
| 32 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.96% | — | +62.04% | |
| 33 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 0.95% | +0.38% | -36.06% | |
| 34 | SIBN | Si-bone Inc | Stock-Other | 0.90% | — | +2.18% | |
| 35 | XTNT | Xtant Medical Holdings Inc | Stock-Other | 0.90% | — | — | |
| 36 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 0.86% | -0.23% | EXIT | |
| 37 | EXK | Exact Sciences CORP | Stock-Materials | 0.84% | — | +1.10% | |
| 38 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.81% | — | -18.55% | |
| 39 | PCVX | Vaxcyte Inc | Stock-Other | 0.80% | — | -51.38% | |
| 40 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.75% | -1.03% | — | |
| 41 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.74% | +0.04% | NEW | |
| 42 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.67% | +0.17% | — | |
| 43 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 0.67% | -0.16% | — | |
| 44 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.67% | — | -2.49% | |
| 45 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.65% | -0.26% | +5.69% | |
| 46 | UHS | Universal Health Services-b | Stock-Healthcare | 0.65% | — | — | |
| 47 | ICLR | ICON Public Limited Company | Stock-Healthcare | 0.65% | — | -28.83% | |
| 48 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.63% | — | -32.57% | |
| 49 | VERA | Vera Therapeutics Inc | Stock-Other | 0.54% | — | — | |
| 50 | BIOA | Bioage Labs Inc | Stock-Other | 0.54% | +0.08% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics Inc | +1.9% | — | Unchanged |
| 2 | MBX | Mbx Biosciences Inc | +1.8% | NEW | New buy |
| 3 | QTTB | Q32 Bio Inc | +1% | — | Unchanged |
| 4 | UNH | Unitedhealth Group Inc | +0.8% | +59.82% | Add |
| 5 | AMGN | Amgen Inc | +0.7% | +87.03% | Add |
| 6 | UHS | Universal Health Services-b | +0.7% | NEW | New buy |
| 7 | SPRY | Ars Pharmaceuticals Inc | +0.6% | -10.31% | Trim |
| 8 | ITGR | Integer Holdings CORP | +0.6% | +64.65% | Add |
| 9 | BIOA | Bioage Labs Inc | +0.5% | NEW | New buy |
| 10 | PHAT | Phathom Pharmaceuticals Inc | +0.5% | NEW | New buy |
| 11 | CGON | Cg Oncology Inc | +0.5% | NEW | New buy |
| 12 | SYK | Stryker CORP | +0.5% | +28.03% | Add |
| 13 | CRVS | Corvus Pharmaceuticals Inc | +0.4% | — | Unchanged |
| 14 | RNAGBP | Avidity Biosciences Inc | +0.4% | +62.04% | Add |
| 15 | REGN | Regeneron Pharmaceuticals | +0.4% | +98.25% | Add |
| 16 | CRBP | Corbus Pharmaceuticals Holdi | +0.3% | NEW | New buy |
| 17 | CCCC | C4 Therapeutics Inc | +0.3% | +199.25% | Add |
| 18 | CMPX | Compass Therapeutics Inc | +0.3% | — | Unchanged |
| 19 | EXK | Exact Sciences CORP | +0.3% | +1.10% | Add |
| 20 | MEDP | Medpace Holdings Inc | +0.3% | NEW | New buy |
| 21 | ARGX | Argenx Se - Adr | +0.2% | -2.20% | Trim |
| 22 | GILD | Gilead Sciences Inc | +0.2% | NEW | New buy |
| 23 | BNTX | Biontech Se-adr | +0.2% | NEW | New buy |
| 24 | GPCR | Structure Therapeutics Inc | +0.2% | +206.96% | Add |
| 25 | ACAD | Acadia Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 26 | AVBP | Arrivent Biopharma Inc | +0.2% | — | Unchanged |
| 27 | AVTX | Avalo Therapeutics Inc | +0.2% | NEW | New buy |
| 28 | OSCR | Oscar Health Inc - Class A | +0.1% | NEW | New buy |
| 29 | 430 | Terns Pharmaceuticals Inc | +0.1% | -0.74% | Trim |
| 30 | BCAX | Bicara Therapeutics Inc | +0.1% | NEW | New buy |
| 31 | NTRA | Natera Inc | +0.1% | — | Unchanged |
| 32 | LXRX | Lexicon Pharmaceuticals Inc | +0.1% | +88.57% | Add |
| 33 | PEPG | Pepgen Inc | +0.1% | NEW | New buy |
| 34 | MRNA | Moderna Inc | +0.1% | NEW | New buy |
| 35 | SRPT | Sarepta Therapeutics Inc | +0.1% | +44.32% | Add |
| 36 | APGE | Apogee Therapeutics Inc | +0.1% | — | Unchanged |
| 37 | ✓ | Longboard Pharmaceuticals In | +0.1% | NEW | New buy |
| 38 | TYRA | Tyra Biosciences Inc | +0.1% | — | Unchanged |
| 39 | VIR | Vir Biotechnology Inc | +0.1% | +54.00% | Add |
| 40 | NMRA | Neumora Therapeutics Inc | +0.1% | — | Unchanged |
| 41 | VSTM | Verastem Inc | +0.1% | +87.20% | Add |
| 42 | ARDT | Ardent Health Inc | +0.1% | NEW | New buy |
| 43 | VERA | Vera Therapeutics Inc | +0.1% | — | Unchanged |
| 44 | TRAW | Traws Pharma Inc | +0.1% | NEW | New buy |
| 45 | ALNY | Alnylam Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 46 | FLNA | Filana Therapeutics Inc | +0.1% | NEW | New buy |
| 47 | TIL | Instil Bio Inc | 0% | NEW | New buy |
| 48 | TORCEUR | Adicet Bio Inc | 0% | — | Unchanged |
| 49 | NKTX | Nkarta Inc | 0% | +85.08% | Add |
| 50 | ✓ | 0% | NEW | New buy |
According to official SEC Form 13F filings, Orbimed Advisors LLC reported a total U.S. public equity portfolio value of $5.4B across 113 disclosed positions in Q3 2024.
During Q3 2024, Orbimed Advisors LLC's top holdings by market value included EWTX (7.3%)、SVA (6.2%)、LLY (5.4%). The largest single position, EWTX, represented 7.3% of total portfolio value.
In Q3 2024, Orbimed Advisors LLC made 89 total portfolio adjustments, initiating 21 new buys, adding to 19 positions, trimming 31 holdings, and fully liquidating 18 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.